Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 1.45
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is 'cheap' on EV/EBITDA.
Data is available to registered users only
